PMID- 33349110
OWN - NLM
STAT- MEDLINE
DCOM- 20211004
LR  - 20211004
IS  - 1477-0962 (Electronic)
IS  - 0961-2033 (Linking)
VI  - 30
IP  - 4
DP  - 2021 Apr
TI  - Drug-induced subacute cutaneous lupus erythematosus associated with abatacept.
PG  - 661-663
LID - 10.1177/0961203320981146 [doi]
AB  - Numerous drugs have been linked to the induction or exacerbation of systemic 
      cutaneous lupus erythematosus (SCLE). This report presents the third case of the 
      biologic abatacept as an exacerbating medication for SCLE. A 73-year old woman 
      with a remote history of subacute cutaneous lupus and rheumatoid arthritis, well 
      controlled on hydroxychloroquine, presented with worsening annular erythematous, 
      slightly scaly plaques on her forearms and hands. She had been started on 
      abatacept a month prior. She was diagnosed with SCLE exacerbated by abatacept 
      given the clinical findings, time course, and skin biopsy with interface 
      dermatitis. Her skin eruption cleared completely several months later after 
      discontinuing abatacept and switching to tociluzumab, while remaining on 
      hydroxychloroquine. This case highlights the need to consider abatacept as a 
      potential exacerbating medication for SCLE in any patient with a new 
      photodistributed papulosquamous eruption.
FAU - Figueredo Zamora, Eliana
AU  - Figueredo Zamora E
AUID- ORCID: 0000-0001-8865-4532
AD  - Division of Dermatology, Department of Medicine, University of Louisville, 
      Louisville, USA.
FAU - Callen, Jeffrey P
AU  - Callen JP
AD  - Division of Dermatology, Department of Medicine, University of Louisville, 
      Louisville, USA.
FAU - Schadt, Courtney R
AU  - Schadt CR
AD  - Division of Dermatology, Department of Medicine, University of Louisville, 
      Louisville, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20201222
PL  - England
TA  - Lupus
JT  - Lupus
JID - 9204265
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 7D0YB67S97 (Abatacept)
RN  - I031V2H011 (tocilizumab)
SB  - IM
MH  - Abatacept/*adverse effects
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Biopsy
MH  - Drug Substitution
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immune Checkpoint Inhibitors/*adverse effects
MH  - Lupus Erythematosus, Cutaneous/*chemically induced/diagnosis
MH  - Skin/pathology
MH  - Treatment Outcome
MH  - Withholding Treatment
OTO - NOTNLM
OT  - Cutaneous lupus
OT  - abatacept
OT  - biologic
OT  - drug induced subacute cutaneous lupus erythematosus
OT  - photodistributed skin lesions
OT  - subacute lupus erythematosus
EDAT- 2020/12/23 06:00
MHDA- 2021/10/05 06:00
CRDT- 2020/12/22 05:31
PHST- 2020/12/23 06:00 [pubmed]
PHST- 2021/10/05 06:00 [medline]
PHST- 2020/12/22 05:31 [entrez]
AID - 10.1177/0961203320981146 [doi]
PST - ppublish
SO  - Lupus. 2021 Apr;30(4):661-663. doi: 10.1177/0961203320981146. Epub 2020 Dec 22.